Alan Landay

Author PubWeight™ 156.36‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006 24.38
2 Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006 8.41
3 Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis 2009 6.17
4 Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 2012 5.52
5 Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science 2004 5.31
6 Susceptibility to human immunodeficiency virus-1 infection of human foreskin and cervical tissue grown in explant culture. Am J Pathol 2002 3.66
7 HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr 2012 2.95
8 Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infect Dis 2010 2.37
9 Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. J Infect Dis 2006 2.26
10 Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study. Anal Chem 2008 2.12
11 Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002 2.02
12 Age-related immune dysfunction in health and in human immunodeficiency virus (HIV) disease: association of age and HIV infection with naive CD8+ cell depletion, reduced expression of CD28 on CD8+ cells, and reduced thymic volumes. J Infect Dis 2003 1.97
13 Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat Med 2002 1.93
14 Coagulation biomarkers predict disease progression in SIV-infected nonhuman primates. Blood 2012 1.91
15 The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328. Arch Intern Med 2007 1.84
16 HIV-1 in genital tract and plasma of women: compartmentalization of viral sequences, coreceptor usage, and glycosylation. Proc Natl Acad Sci U S A 2003 1.71
17 Interleukin-7-treated naive T cells can be productively infected by T-cell-adapted and primary isolates of human immunodeficiency virus 1. Blood 2002 1.70
18 Treatment of intestinal worms is associated with decreased HIV plasma viral load. J Acquir Immune Defic Syndr 2002 1.59
19 Early immune senescence in HIV disease. Curr HIV/AIDS Rep 2010 1.58
20 CD8(+) T cell activation in women coinfected with human immunodeficiency virus type 1 and hepatitis C virus. J Infect Dis 2008 1.49
21 Reducing the burden of HIV/AIDS in infants: the contribution of improved diagnostics. Nature 2006 1.48
22 Whole-blood interleukin-18 level during early HIV-1 infection is associated with reduced CXCR4 coreceptor expression and interferon- gamma levels. J Infect Dis 2007 1.42
23 Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus. J Infect Dis 2010 1.42
24 Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women with a high risk of heterosexual acquisition of HIV infection. Clin Vaccine Immunol 2007 1.41
25 Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses 2012 1.35
26 Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells. J Infect Dis 2006 1.32
27 Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS Clinical Trials Group study. J Infect Dis 2006 1.31
28 CD4 immunophenotyping in HIV infection. Nat Rev Microbiol 2008 1.27
29 Infection of CD127+ (interleukin-7 receptor+) CD4+ cells and overexpression of CTLA-4 are linked to loss of antigen-specific CD4 T cells during primary human immunodeficiency virus type 1 infection. J Virol 2006 1.23
30 Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response. J Infect Dis 2004 1.21
31 A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115. Antivir Ther 2007 1.17
32 A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256. J Infect Dis 2012 1.17
33 Early microbial translocation blockade reduces SIV-mediated inflammation and viral replication. J Clin Invest 2014 1.14
34 Reducing the burden of sexually transmitted infections in resource-limited settings: the role of improved diagnostics. Nature 2006 1.13
35 Cell-associated genital tract virus and vertical transmission of human immunodeficiency virus type 1 in antiretroviral-experienced women. J Infect Dis 2003 1.11
36 The relationship of T-regulatory cell subsets to disease stage, immune activation, and pathogen-specific immunity in HIV infection. J Acquir Immune Defic Syndr 2008 1.10
37 GBV-C viremia is associated with reduced CD4 expansion in HIV-infected people receiving HAART and interleukin-2 therapy. AIDS 2009 1.09
38 A North American multilaboratory study of CD4 counts using flow cytometric panLeukogating (PLG): a NIAID-DAIDS Immunology Quality Assessment Program Study. Cytometry B Clin Cytom 2008 1.06
39 Interferon-alpha administration enhances CD8+ T cell activation in HIV infection. PLoS One 2012 1.06
40 Resumption of HIV replication is associated with monocyte/macrophage derived cytokine and chemokine changes: results from a large international clinical trial. AIDS 2011 1.05
41 The role of bacterial vaginosis and trichomonas in HIV transmission across the female genital tract. Curr HIV Res 2012 1.05
42 HIV-1-infected antiretroviral-treated patients with prolonged partial viral suppression: clinical, virologic, and immunologic course. J Acquir Immune Defic Syndr 2003 1.05
43 Long-term changes in circulating CD4 T lymphocytes in virologically suppressed patients after 6 years of highly active antiretroviral therapy. AIDS 2004 1.03
44 MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study. J Acquir Immune Defic Syndr 2003 1.01
45 Mother-to-child transmission of HIV-1: strong association with certain maternal HLA-B alleles independent of viral load implicates innate immune mechanisms. J Acquir Immune Defic Syndr 2004 1.01
46 CD1d-restricted natural killer T cells are potent targets for human immunodeficiency virus infection. Immunology 2003 1.01
47 Regulatory B cell frequency correlates with markers of HIV disease progression and attenuates anti-HIV CD8⁺ T cell function in vitro. J Leukoc Biol 2013 1.01
48 Distinct mechanisms of T cell reconstitution can be identified by estimating thymic volume in adult HIV-1 disease. J Infect Dis 2005 1.00
49 CD28-negative CD4+ and CD8+ T cells in antiretroviral therapy-naive HIV-infected adults enrolled in adult clinical trials group studies. J Infect Dis 2012 0.98
50 Immune responses to abacavir in antigen-presenting cells from hypersensitive patients. AIDS 2007 0.96
51 HIV type 1 and cytomegalovirus coinfection in the female genital tract. J Infect Dis 2004 0.95
52 Plasma levels of cytokines and chemokines and the risk of mortality in HIV-infected individuals: a case-control analysis nested in a large clinical trial. AIDS 2015 0.95
53 Immunophenotypic alterations in acute and early HIV infection. Clin Immunol 2007 0.94
54 Early and delayed benefits of HIV-1 suppression: timeline of recovery of innate immunity effector cells. AIDS 2007 0.94
55 Human cytomegalovirus and human immunodeficiency virus type-1 co-infection in human cervical tissue. Virology 2007 0.93
56 Chemokine analogues show suitable stability for development as microbicides. J Acquir Immune Defic Syndr 2008 0.93
57 Intracellular Casp8p41 content is inversely associated with CD4 T cell count. J Infect Dis 2010 0.93
58 GB virus C infection is associated with altered lymphocyte subset distribution and reduced T cell activation and proliferation in HIV-infected individuals. PLoS One 2012 0.92
59 Increased glucose metabolic activity is associated with CD4+ T-cell activation and depletion during chronic HIV infection. AIDS 2014 0.92
60 Proinflammatory and type 1 cytokine expression in cervical mucosa during HIV-1 and human papillomavirus infection. J Acquir Immune Defic Syndr 2007 0.91
61 Longitudinal assessment of pigtailed macaque lower genital tract microbiota by pyrosequencing reveals dissimilarity to the genital microbiota of healthy humans. AIDS Res Hum Retroviruses 2012 0.91
62 Interleukin-2 Increases CD4+ lymphocyte numbers but does not enhance responses to immunization: results of A5046s. J Infect Dis 2003 0.90
63 Role of Baseline pol Genotype in HIV-1 Fitness Evolution. J Acquir Immune Defic Syndr 2003 0.89
64 Dysfunctional natural killer cells, in vivo, are governed by HIV viremia regardless of whether the infected individual is on antiretroviral therapy. AIDS 2007 0.89
65 A Phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection. AIDS 2002 0.88
66 Dynamics of cytokine expression in HIV productively infected primary CD4+ T cells. Blood 2004 0.88
67 Interleukin-7 induces HIV replication in primary naive T cells through a nuclear factor of activated T cell (NFAT)-dependent pathway. Virology 2006 0.87
68 Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir. AIDS Res Hum Retroviruses 2010 0.86
69 Interleukin-7 signalling is sufficient to phenotypically and functionally prime human CD4 naive T cells. Immunology 2005 0.86
70 The menstrual cycle does not affect human immunodeficiency virus type 1 levels in vaginal secretions. J Infect Dis 2002 0.86
71 GB virus C infection and B-cell, natural killer cell, and monocyte activation markers in HIV-infected individuals. AIDS 2013 0.86
72 Older HIV-infected patients on antiretroviral therapy have B-cell expansion and attenuated CD4 cell increases with immune activation reduction. AIDS 2013 0.85
73 Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328). AIDS Res Ther 2010 0.84
74 Immune recovery in HIV disease: role of the thymus and T cell expansion in immune reconstitution strategies. J Hematother Stem Cell Res 2002 0.84
75 Entrapment of recent thymic emigrants in lymphoid tissues from HIV-infected patients: association with HIV cellular viral load. AIDS 2002 0.83
76 CCR5 and CXCR4 expression after highly active antiretroviral therapy (HAART). J Acquir Immune Defic Syndr 2002 0.82
77 Association of HIV clinical disease progression with profiles of early immune activation: results from a cluster analysis approach. AIDS 2013 0.82
78 Trophoblasts are productively infected by CD4-independent isolate of HIV type 1. AIDS Res Hum Retroviruses 2002 0.82
79 Can immune markers predict subsequent discordance between immunologic and virologic responses to antiretroviral therapy? Adult AIDS Clinical Trials Group. Clin Infect Dis 2003 0.81
80 Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infection. J Infect Dis 2003 0.81
81 Biology of mucosally transmitted sexual infection-translating the basic science into novel HIV intervention: a workshop summary. AIDS Res Hum Retroviruses 2012 0.80
82 A role for TLR signaling during B cell activation in antiretroviral-treated HIV individuals. AIDS Res Hum Retroviruses 2013 0.80
83 Association of cells with natural killer (NK) and NKT immunophenotype with incident cancers in HIV-infected women. AIDS Res Hum Retroviruses 2008 0.80
84 HIV infection of primary CD4+ Th2 cells, defined by expression of the chemoattractant receptor-homologous (CRTH2), induces a Th0 phenotype. AIDS Res Hum Retroviruses 2007 0.79
85 The relation of plasmacytoid dendritic cells (pDCs) and regulatory T-cells (Tregs) with HPV persistence in HIV-infected and HIV-uninfected women. Viral Immunol 2014 0.78
86 Effector and regulatory roles for B cells in HIV infection? Autoimmunity 2012 0.78
87 Research needs and challenges in the development of HIV diagnostic and treatment monitoring tests for use in resource-limited settings. Curr Opin HIV AIDS 2008 0.78
88 Interleukin 10 responses are associated with sustained CD4 T-cell counts in treated HIV infection. J Infect Dis 2012 0.78
89 Proliferation responses to HIVp24 during antiretroviral therapy do not reflect improved immune phenotype or function. AIDS 2004 0.78
90 Using the pathogenic and nonpathogenic nonhuman primate model for studying non-AIDS comorbidities. Curr HIV/AIDS Rep 2015 0.78
91 Association of selected phenotypic markers of lymphocyte activation and differentiation with perinatal human immunodeficiency virus transmission and infant infection. Clin Diagn Lab Immunol 2005 0.77
92 Enhanced antibody responses elicited by a CpG adjuvant do not improve the protective effect of an aldrithiol-2-inactivated simian immunodeficiency virus therapeutic AIDS vaccine. Clin Vaccine Immunol 2009 0.77
93 Systemic Immune Activation and HIV Shedding in the Female Genital Tract. J Acquir Immune Defic Syndr 2016 0.77
94 Key Concepts in the Early Immunology of HIV-1 Infection. Curr Infect Dis Rep 2012 0.76
95 A randomized trial of interleukin-2 during withdrawal of antiretroviral treatment. J Interferon Cytokine Res 2011 0.76
96 Impact of Hepatitis C Virus on the Circulating Levels of IL-7 in HIV-1 Coinfected Women. J Acquir Immune Defic Syndr 2016 0.75
97 Loneliness in Older Black Adults with Human Immunodeficiency Virus Is Associated with Poorer Cognition. Gerontology 2017 0.75
98 Liver X receptor alpha (LXRalpha) as a therapeutic target in chronic lymphocytic leukemia (CLL). J Leukoc Biol 2009 0.75
99 Monitoring processed, mature Human Immunodeficiency Virus type 1 particles immediately following treatment with a protease inhibitor-containing treatment regimen. AIDS Res Ther 2005 0.75
100 Correction: Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial. PLoS Pathog 2016 0.75
101 Dysregulated B-cell TLR2 expression and elevated regulatory B-cell frequency precede the diagnosis of AIDS-related non-Hodgkin lymphoma. AIDS 2015 0.75
102 HIV immunology better understood and vaccination attempts started. AIDS 2002 0.75
103 Correction: Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial. PLoS Pathog 2017 0.75
104 Immune reconstitution after successful treatment with protease inhibitor-based and protease inhibitor-sparing antiretroviral regimens. J Acquir Immune Defic Syndr 2002 0.75